ArticleNature2018
A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 250 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
250citing papers in PubMed, 1 pooled it
28.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
250 citing papers in PubMed, 1 synthesis or guideline pooled it, 398 citations in OpenAlex.
- Pooled it
- Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.The New England journal of medicine · 2024Trial
- Aberrant expression of MERTK activates BCR via CD79a in CLL cells: alternative therapeutic strategy for relapsed/refractory CLL.Leukemia · 2026Article
- Oncogenic Mutations and Tumor Microenvironment Alterations in Diffuse Large B-Cell Lymphoma With Bulky Disease.Cancer medicine · 2026Article
- Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma.Haematologica · 2026Article
- Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models.Blood neoplasia · 2026Article
- Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy.Cells · 2026Review
- BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88Journal of hematology & oncology · 2026Article
- NPC2 deficiency as a potential target drives malignancy and chemo-resistance in DLBCL.Biology direct · 2026Article
- The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities.Blood cancer discovery · 2026Review
- Article
- GLUT1-mediated glucose flux constrains autoreactive but not foreign antigen-specific B-cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes.Annual review of cancer biology · 2026Article
- Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).International journal of oncology · 2026Review
- Chemical biology approaches to study and target circadian clocks and their components.FEBS letters · 2026Review
- Inhibition of autoantigen-induced B-cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL).Cell death & disease · 2026Article
- Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.Blood advances · 2026Article
- RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.bioRxiv : the preprint server for biology · 2026Article
- TAF7 accumulates in the cytoplasm during cellular transformation and engages STAT3, WASH, and CCT.Frontiers in cell and developmental biology · 2026Article
190 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 16 institutions in 5 countries.
James D PhelanLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ryan M YoungLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Daniel E WebsterLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sandrine RoullandLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
George W WrightBiometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Monica KasbekarLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Arthur L ShafferLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michele CeribelliDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Gaithersburg, MD, USA.
James Q WangLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Roland SchmitzLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Masao NakagawaLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Emmanuel BachyLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Da Wei HuangLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Yanlong JiDepartment of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany.
Lu ChenDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Gaithersburg, MD, USA.
Yandan YangLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hong ZhaoLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Xin YuLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Weihong XuLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Maryknoll M PalisocLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Racquel R ValadezLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Theresa Davies-HillLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Wyndham H WilsonLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Wing C ChanDepartments of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Elaine S JaffeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Randy D GascoyneBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Elias CampoHospital Clinic, University of Barcelona, Barcelona, Spain.
Andreas RosenwaldInstitute of Pathology, University of Würzburg, and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
Jan DelabieUniversity Health Network, Laboratory Medicine Program, Toronto General Hospital and University of Toronto, Toronto, Ontario, Canada.
Lisa M RimszaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA.
Fausto J RodriguezDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fayez EstephanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Matthias HoldhoffDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael J KruhlakExperimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stephen M HewittExperimental Pathology Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Craig J ThomasLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stefania PittalugaLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Thomas OellerichLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. thomas.oellerich@kgu.de.
Louis M StaudtLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. lstaudt@mail.nih.gov.
National Cancer Institute · USNational Institutes of Health · USCenter for Cancer Research · USJohns Hopkins University · USBC Cancer Agency · CACity Of Hope National Medical Center · USDeutschen Konsortium für Translationale Krebsforschung · DEDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEGoethe University Frankfurt · DEInserm · FRMayo Clinic in Arizona · USNational Center for Advancing Translational Sciences · USSidney Kimmel Comprehensive Cancer Center · USUniversitat de Barcelona · ESUniversity of Toronto · CAUniversity of Würzburg · DE
Funding
RNA interference-based screens for molecular targets in cancerZIABC011007 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0MOncogenic mechanisms and molecular targets in lymphomaZIABC011008 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0MExperimental Pathology Laboratory (EPL)ZICBC011638 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2015 to 2025
$16.6MHTS enabled examination of drug combinationsZIATR000047 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI THOMAS, CRAIG · 2015 to 2025
$7.1MMolecular Diagnosis and Prognosis in Aggressive LymphomaU01CA157581 · NCI · UNIVERSITY OF ARIZONA · PI RIMSZA, LISA · 2011 to 2015
$3.1MOncogenic mechanisms and molecular targets in lymphomaZ01BC011008 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2008 to 2008
$770kIntramural NIH HHS Z01 BC011008NCI NIH HHS U01 CA157581
Abstract
B cell receptor (BCR) signalling has emerged as a therapeutic target in B cell lymphomas, but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a subset of patients
Indexed as
CarcinogenesisSignal TransductionAdenineAnimalsBiopsyCRISPR-Cas SystemsDrug DesignFemaleHumansLymphoma, Large B-Cell, DiffuseMiceMultiprotein ComplexesMutationMyeloid Differentiation Factor 88NF-kappa BPiperidinesAdenineibrutinibMTOR protein, humanMultiprotein ComplexesMYD88 protein, humanMyeloid Differentiation Factor 88NF-kappa BPiperidinesPyrazolesPyrimidinesReceptors, Antigen, B-CellTLR9 protein, humanToll-Like Receptor 9TOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.